These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19141025)

  • 1. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Tanioka D; Iwasaki Y; Araki Y; Osawa T; Ikeda H; Ando M; Kobashi H; Sakaguchi K; Shiratori Y; Yamamoto K
    Liver Int; 2009 May; 29(5):721-9. PubMed ID: 19141025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C.
    Kryczka W; Zarebska-Michaluk D; Chrapek M
    Med Sci Monit; 2003 Aug; 9 Suppl 3():32-5. PubMed ID: 15156609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
    Hofer H; Osterreicher C; Jessner W; Penz M; Steindl-Munda P; Wrba F; Ferenci P
    J Hepatol; 2004 Jun; 40(6):1018-22. PubMed ID: 15158344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.
    Mangia A; Leandro G; Helbling B; Renner EL; Tabone M; Sidoli L; Caronia S; Foster GR; Zeuzem S; Berg T; Di Marco V; Cino N; Andriulli A
    J Hepatol; 2004 Mar; 40(3):478-83. PubMed ID: 15123363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).
    Cammà C; Giunta M; Chemello L; Alberti A; Toyoda H; Trepo C; Marcellin P; Zahm F; Schalm S; Craxì A
    Hepatology; 1999 Sep; 30(3):801-7. PubMed ID: 10462389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
    Izumi N; Yasuhiro A; Kurosaki M; Onuki Y; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Nakanishi H; Uchihara M; Miyake S
    Intervirology; 2005; 48(1):59-63. PubMed ID: 15785091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hepatitis C: retreatment of relapsers. An evidence-based approach.
    Cammà C; Craxì A
    Semin Gastrointest Dis; 2000 Apr; 11(2):115-21. PubMed ID: 10803635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver function under interferon/ribavirin therapy of chronic hepatitis C.
    Stintzing S; Schmitt C; Ocker M; Ganslmayer M; Zopf S; Gahr S; Hahn EG; Herold C
    Hepatogastroenterology; 2009; 56(90):462-5. PubMed ID: 19579621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Sho Y; Fujisaki K; Sakashita H; Yamaguchi K; Tahara K; Kubozono O; Ido A; Tsubouchi H
    J Gastroenterol; 2004 Dec; 39(12):1202-4. PubMed ID: 15622486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
    Tran HA; Malcolm Reeves GE; Gibson R; Attia JR
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1163-8. PubMed ID: 19682190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-based therapy of hepatitis C.
    Chevaliez S; Pawlotsky JM
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1222-41. PubMed ID: 17869375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing treatment outcomes in chronic hepatitis C: management of non-response.
    Pol S; Bourlière M
    Antivir Ther; 2006; 11(8):955-70. PubMed ID: 17302365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
    Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial neural network model is superior to logistic regression model in predicting treatment outcomes of interferon-based combination therapy in patients with chronic hepatitis C.
    Wang CH; Mo LR; Lin RC; Kuo JJ; Chang KK; Wu JJ
    Intervirology; 2008; 51(1):14-20. PubMed ID: 18309244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.